Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9056 · 2 trials · 1 indication
The number of participants with greater to or equal to 20% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, disease activity and physical function; physician's assessment of disease activity; and CRP) after 6 months' treatment
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Etanercept 50mg, subcutaneous, once weekly |
| 2 | EXPERIMENTAL | 50mg oral, once daily |
| 3 | EXPERIMENTAL | 100 mg oral, once daily |
| 4 | EXPERIMENTAL | 200 mg oral, once daily |
| 5 | EXPERIMENTAL | 400mg once, daily |
| 6 | PLACEBO_COMPARATOR | oral, once daily |
| Name | Type | Description |
|---|---|---|
| AZD9056 | DRUG | - |
| Etanercept | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Diagnosis of RA with active disease defined as: ≥4 swollen joints and ≥6 tender/painful joints, and either have (blood tests) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). At least one of the following: documented history and current presence of po...
Top 20 of 28 competitors
AZD9056 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It has been evaluated in clinical trials involving patients with rheumatoid arthritis and in healthy volunteers for safety and drug interaction studies. The drug is not approved and remains in clinical development.
AZD9056 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca has sponsored clinical trials of AZD9056 in rheumatoid arthritis and healthy volunteers.
AZD9056 has completed a Phase 2b clinical trial in patients with rheumatoid arthritis. It has also completed Phase 1 studies in healthy volunteers. The drug is investigational and has not received regulatory approval.
AZD9056 has been studied in two completed trials. NCT00520572 was a Phase 2b randomized, double-blind, placebo-controlled study in 385 patients with rheumatoid arthritis. NCT00700986 was a Phase 1 crossover study in 12 healthy male volunteers to investigate retinal function. NCT00736606 was a Phase 1 drug interaction study with simvastatin in healthy volunteers.
AZD9056 is the sole name used for this investigational drug in clinical trial records. No alternative names have been associated with it in the available trial information.